000 02309na a2200313 4500
999 _c4547
_d4547
003 pc4547
005 20190725123107.0
008 130622s2013 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _aMartínez López, Joaquín
_9389
_eHematología y Hemoterapia
245 0 0 _aDownregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.
_h[artículo]
260 _bLeukemia,
_c2013
300 _a27(4):925-31.
500 _aFormato Vancouver: Río-Machín A, Ferreira BI, Henry T, Gómez-López G, Agirre X, Alvárez S. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013 Apr;27(4):925-31.
501 _aPMID: 23174883
504 _aContiene 34 referencias
520 _aCurrently, multiple myeloma (MM) patients are broadly grouped into a non-hyperdiploid (nh-MM) group, highly enriched for IgH translocations, or into a hyperdiploid (h-MM) group, which is typically characterized by trisomies of some odd-numbered chromosomes. We compared the micro RNA (miRNA) expression profiles of these two groups and we identified 16 miRNAs that were downregulated in the h-MM group, relative to the nh-MM group. We found that target genes of the most differentially expressed miRNAs are directly involved in the pathogenesis of MM; specifically, the inhibition of hsa-miR-425, hsa-miR-152 and hsa-miR-24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH chromosomal translocations occurring in nh-MM. Importantly, we showed that the downregulation of these specific miRNAs and the upregulation of their targets also occur simultaneously in primary cases of h-MM. These data provide further evidence on the unifying role of cyclin D pathways deregulation as the key mechanism involved in the development of both groups of MM. Finally, they establish the importance of miRNA deregulation in the context of MM, thereby opening up the potential for future therapeutic approaches based on this molecular mechanism.
710 _9297
_aServicio de Hematología y Hemoterapia
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/4/pc4547.pdf
_ySolicitar documento
942 _n0
_2ddc
_cART